Host ANGPTL2 establishes an immunosuppressive tumor microenvironment and resistance to immune checkpoint therapy
Cancer Science · 2024
DOI: 10.1111/cas.16348 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Shinsei Yumoto und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan. Hauptthemen laut MEDLINE: Angiopoietin-Like Protein 2, Tumor Microenvironment, Immune Checkpoint Inhibitors, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Takeda Science Foundation, Ministry of Education, Culture, Sports, Science and Technology.
Abstract (Originalsprache)
Use of immune checkpoint inhibitors (ICIs) as cancer immunotherapy has advanced rapidly in the clinic; however, mechanisms underlying resistance to ICI therapy, including impaired T cell infiltration, low immunogenicity, and tumor “immunophenotypes” governed by the host, remain unclear. We previously reported that in some cancer contexts, tumor cell‐derived angiopoietin‐like protein 2 (ANGPTL2) has tumor‐promoting functions. Here, we asked whether ANGPTL2 deficiency could enhance antitumor ICI activity in two inflammatory contexts: a murine syngeneic model of colorectal cancer and a mouse model of high‐fat diet (HFD)‐induced obesity. Systemic ANGPTL2 deficiency potentiated ICI efficacy in the syngeneic model, supporting an immunosuppressive role for host ANGPTL2. Relevant to the mechanism, we found that ANGPTL2 induces pro‐inflammatory cytokine production in adipose tissues, driving generation of myeloid‐derived suppressor cells (MDSCs) in bone marrow and contributing to an immunosuppressive tumor microenvironment and resistance to ICI therapy. Moreover, HFD‐induced obese mice showed impaired responsiveness to ICI treatment, suggesting that obesity‐induced chronic inflammation facilitated by high ANGPTL2 expression blocks ICI antitumor effects. Our findings overall provide novel insight into protumor ANGPTL2 functions and illustrate the essential role of the host system in ICI responsiveness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Genetics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
- Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
- Department of Aging and Geriatric Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
- Center for Metabolic Regulation of Healthy Aging (CMHA), Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
- Department of Molecular and Medical Pharmacology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
ORCID-Profile: Haruki Horiguchi, Tsuyoshi Kadomatsu, Taichi Horino, Toshiro Moroishi, Hideo Baba
Förderung
- Takeda Science Foundation
- Ministry of Education, Culture, Sports, Science and Technology
Zitieren
APA
Yumoto, S., Horiguchi, H., Kadomatsu, T., Horino, T., Sato, M., Terada, K., Miyata, K., Moroishi, T., Baba, H., & Oike, Y. (2024). Host ANGPTL2 establishes an immunosuppressive tumor microenvironment and resistance to immune checkpoint therapy. Cancer Science. https://doi.org/10.1111/cas.16348
Vancouver
Yumoto S, Horiguchi H, Kadomatsu T, Horino T, Sato M, Terada K, et al. Host ANGPTL2 establishes an immunosuppressive tumor microenvironment and resistance to immune checkpoint therapy. Cancer Science. 2024. doi:10.1111/cas.16348
BibTeX
@article{Yumoto2024,
author = {Yumoto, Shinsei and Horiguchi, Haruki and Kadomatsu, Tsuyoshi and Horino, Taichi and Sato, Michio and Terada, Kazutoyo and Miyata, Keishi and Moroishi, Toshiro and Baba, Hideo and Oike, Yuichi},
title = {Host ANGPTL2 establishes an immunosuppressive tumor microenvironment and resistance to immune checkpoint therapy},
journal = {Cancer Science},
year = {2024},
doi = {10.1111/cas.16348}
}
EUVIMED